2025-08-29 05:26:52
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Lincoln Pharmaceuticals Ltd posts consolidated PAT of Rs. 21.61 crores in Q3 FY2023
Posted On : 2023-02-09 13:42:11( TIMEZONE : IST )
Lincoln Pharmaceuticals Limited has reported Consolidated financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 140.1238 crores during the period ended December 31, 2022 as compared to Rs. 146.3335 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. 21.621 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 23.7129 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. 10.79 for the period ended December 31, 2022 as compared to Rs. 11.84 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹140.1238 crs | ₹146.3335 crs |  -4.24% |
| Net Profit | ₹21.621 crs | ₹23.7129 crs | -8.82% |
| EPS | ₹10.79 | ₹11.84 | -8.87% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.140.1238 crores during the period ended December 31, 2022 as compared to Rs.122.5157 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.21.621 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.17.6019 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.10.79 for the period ended December 31, 2022 as compared to Rs.8.79 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹140.1238 crs | ₹122.5157 crs |  14.37% |
| Net Profit | ₹21.621 crs | ₹17.6019 crs | 22.83% |
| EPS | ₹10.79 | ₹8.79 | 22.75% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.416.4229 crores during the 9 Months period ended December 31, 2022 as compared to Rs.377.6434 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.60.3376 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.58.3313 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.30.12 for the 9 Months period ended December 31, 2022 as compared to Rs.29.12 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹416.4229 crs | ₹377.6434 crs | 10.27% |
| Net Profit | ₹60.3376 crs | ₹58.3313 crs | 3.44% |
| EPS | ₹30.12 | ₹29.12 | 3.43% |
Shares of Lincoln Pharmaceuticals Limited was last trading in BSE at Rs. 322.30 as compared to the previous close of Rs. 311.55. The total number of shares traded during the day was 3256 in over 250 trades.
The stock hit an intraday high of Rs. 339.45 and intraday low of 309.00. The net turnover during the day was Rs. 1038795.00.
